An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Launched by BEIJING INNOCARE PHARMA TECH CO., LTD. · Jul 28, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ICP-192 for people with bladder urothelial cancer that cannot be surgically removed or has spread to other parts of the body. It is a phase 2 trial, which means it's testing whether this treatment is effective and safe for patients. The study is currently looking for participants aged 18 and older, regardless of gender, who have been diagnosed with this type of cancer and have at least one measurable tumor. Participants should also be in good enough health to expect to live for at least three more months.

If you decide to join the trial, you will receive ICP-192, and the researchers will closely monitor your health and any side effects you may experience. This trial is open to individuals who have not previously received certain types of cancer treatments and do not have specific eye conditions that could increase the risk of side effects. Overall, this study aims to provide more information about how well ICP-192 works for patients with this challenging form of cancer.

Gender

ALL

Eligibility criteria

• • Inclusion criteria：
• • 1. Signed the ICF and Age ≥ 18 years old, either sex.
• • 2. ECOG ≤ 1.
• • 3. Life expectancy of at least 3 months.
• • 4. Histologically confirmed unresectable or metastatic bladder urothelial cancinoma.
• • 5. At least one measurable lesion as the target lesion at screening assessed according to RECIST V1.1
• Exclusion Criteria:
• • 1. Prior treatment with selective FGFR inhibitors or FGFR antibodies.
• • 2. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity.